Skip to main content

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

*January 2020*

Oncoprex in combination with osimertinib (Tagrisso) received fast track designation from the FDA to treat patients with non-small cell lung cancer (NSCLC) with EFGR mutations that progressed after treatment with osimertinib alone, according to Genprex, Inc., the immunogene therapy’s manufacturer.

Read more.